Unique ID issued by UMIN | UMIN000034160 |
---|---|
Receipt number | R000038945 |
Scientific Title | Effect of Whey Protein Supplement on Plasma Glucose Levels in Japanese Patients with Inadequately Controlled Type 2 Diabetes |
Date of disclosure of the study information | 2020/12/31 |
Last modified on | 2021/03/18 12:11:09 |
Effect of Whey Protein Supplement on Plasma Glucose Levels in Japanese Patients with Inadequately Controlled Type 2 Diabetes
Effect of Whey Protein Supplement on Plasma Glucose Levels
Effect of Whey Protein Supplement on Plasma Glucose Levels in Japanese Patients with Inadequately Controlled Type 2 Diabetes
Effect of Whey Protein Supplement on Plasma Glucose Levels
Japan |
Type 2 diabetes
Endocrinology and Metabolism |
Others
NO
Inspect the effect of whey protein supplement on plasma glucose levels
Efficacy
The change of the HbA1c from baseline in the whey protein supplement performed after each 12 weeks
The change of the GA, GLP-1, GIP and PYY from baseline in the whey protein supplement performed after each 12 weeks
And the change of body composition by the Bioelectrical Impedance Analysis
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Food |
Trained nutritionists calculate ideal body weight and assess their daily diet.
Patients were instructed to add on 10% of total energy by whey protein supplement.
20 | years-old | <= |
Not applicable |
Male and Female
1)Outpatients.
2)HbA1c before clinical trial start is 7.0% or more and 8.0% less.
3)Over 20years old. Gender unquestioned.
4)Patients are being treated DPP-4 inhibitor for more than 6 months,and variation of HbA1c by <0.5% whithin 3 months before recruitment.
5)Written informed consent was obtained from all participants.
1)Type1 diabetic patients and Type2 diabetic patients who depend on insulin.
2)Patients have renal failure (estimated glomerular filtration rate <60mL/min/1.73m2).
3)Patients have severe liver disfunction.
4)Women who may be pregnant, may become pregnant and are breastfeeding.
5)Patients have malignancy or had treated to malignancy past five years.
6)Patients have admission to improve glycemic control within a past year before written consent.
7)Patients are using a drug with the influence for glucose metabolism (steroid, interferon, hormone drugs, antipsychotic drugs and antitubercular drugs).
8)Patients have allergy to protein or dairy product.
9)Patients who were judged to be ineligible by the investigator.
70
1st name | Yasushi |
Middle name | |
Last name | Tanaka |
St. Marianna University School of Medicine
Division of Metabolism and endocrinology, Depertment of Internal Medicine
2168511
2-16-1 Sugao, Miyamae-ku, Kawaski, Kanagawa, Japan.
044-977-8111
smu.tainai@gmail.com
1st name | Yutaro |
Middle name | |
Last name | Yamamoto |
St. Marianna University School of Medicine
Division of Metabolism and endocrinology, Depertment of Internal Medicine
2168511
2-16-1 Sugao, Miyamae-ku, Kawaski, Kanagawa, Japan.
044-977-8111
y3yamamoto@marianna-u.ac.jp
St. Marianna University School of Medicine
None
Self funding
St. Marianna University School of Medicine
2-16-1 Sugao, Miyamae-ku, Kawaski, Kanagawa, Japan.
044-977-8111
k-sienbu.mail@marianna-u.ac.jp
NO
聖マリアンナ医科大学病院(神奈川県)
2020 | Year | 12 | Month | 31 | Day |
none
Unpublished
none
0
Stopped as it falls under specific clinical research.
2021 | Year | 03 | Month | 18 | Day |
none
none
none
none
Terminated
2018 | Year | 05 | Month | 07 | Day |
2018 | Year | 05 | Month | 15 | Day |
2018 | Year | 10 | Month | 01 | Day |
2019 | Year | 12 | Month | 31 | Day |
2018 | Year | 09 | Month | 15 | Day |
2021 | Year | 03 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038945